Blood Plasma Derivatives Market Report 2026

Blood Plasma Derivatives Market Overview

• Blood Plasma Derivatives market size has reached to $55.76 billion in 2025 • Expected to grow to $86.68 billion in 2030 at a compound annual growth rate (CAGR) of 9.3% • Growth Driver: Rising Hemophilia Prevalence Ignites Growth In The Blood Plasma Derivatives Market • Market Trend: Major Players Prioritize Supply Chain Innovation To Advance Plasma-Derived Therapies • North America was the largest region in 2025.

What Is Covered Under Blood Plasma Derivatives Market?

Blood plasma derivatives are medicinal products crafted from refined proteins found in blood plasma, encompassing clotting factors, albumins, and other proteins employed to treat diverse medical ailments. These derivatives hold significant significance as they aid in replenishing absent or inadequate proteins within the body. The main types of blood plasma derivatives are albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. Albumin refers to an essential protein present in blood plasma derivatives that aids in the regulation of osmotic pressure within the blood and facilitates the transportation of hormones, metals, and other molecules throughout the body. These are used in several applications, such as hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand's disease, and others, which are used by various end-users, including hospitals, clinics, and others.

What Is The Blood Plasma Derivatives Market Growth Forecast?

The blood plasma derivatives market size is expected to see strong growth in the next few years. It will grow to $86.68 billion in 2030 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to increasing prevalence of immunodeficiency diseases, rising investments in plasma-derived therapeutics, expansion of global plasma donation networks, growing focus on self-sufficiency in plasma supply, advancements in recombinant protein technologies. Major trends in the forecast period include increasing demand for immunoglobulin therapies, rising adoption of recombinant plasma products, expansion of fractionation and purification technologies, growing focus on pathogen reduction processes, enhanced cold chain and plasma processing efficiency.

Global Blood Plasma Derivatives Market Segmentation

1) By Type: Albumin, Factor VIII, Factor IX, Immunoglobulin, Hyperimmune Globulin, Other Types 2) By Application: Hemophilia, Hypogammaglobulinemia, Immunodeficiency Diseases, Von Willebrand's Disease, Other Applications 3) By End-User: Hospitals, Clinics, Other End-Users Subsegments: 1) By Albumin: Human Serum Albumin, Recombinant Albumin 2) By Factor VIII: Plasma-Derived Factor VIII, Recombinant Factor VIII 3) By Factor IX: Plasma-Derived Factor IX, Recombinant Factor IX 4) By Immunoglobulin: Intravenous Immunoglobulin (IVIG), Subcutaneous Immunoglobulin (SCIG) 5) By Hyperimmune Globulin: Specific Pathogen-Reduced Hyperimmune Globulin, Standard Hyperimmune Globulin 6) By Other Types: Fibrinogen, Clotting Factor Concentrates, Plasma-Derived Proteins

What Is The Driver Of The Blood Plasma Derivatives Market?

The increasing prevalence of hemophilia is expected to drive the growth of the blood plasma derivatives market. Hemophilia refers to a bleeding problem that is hereditary and causes the blood to not clot properly. This may result in both spontaneous bleeding and bleeding after injury or surgery. In people with hereditary or acquired problems with hemostasis, blood plasma-derived products or medications can effectively improve hemostasis. Treatment for hemophilia A, von Willebrand disease, and hemophilia B uses factor VIII, factor VIII/vWF, and factor IX concentrates, respectively. For instance, in October 2025, according to the World Federation of Hemophilia (WFH) Annual Global Survey (AGS) In 2024, the data reveals a 6% rise in the global identification of individuals with hemophilia, a 6% rise in those identified with VWD, and a 9% rise in the detection of other inherited bleeding disorders. Therefore, the increasing prevalence of hemophilia is driving the growth of the blood plasma derivatives industry.

Key Players In The Global Blood Plasma Derivatives Market

Major companies operating in the blood plasma derivatives market are Bayer AG, Sanofi S.A., Takeda Pharmaceutical Company Limited, Baxter International Inc., CSL Limited, Meiji Group, Grifols S.A., Shire Pharmaceuticals Inc., GC Biopharma Corp, Emergent BioSolutions Inc., Shanghai Raas Blood Products Co Ltd., Kedrion S.p.A., Sanquin, Biotest AG, Bio Products Ltd., ADMA Biologics Inc., China Biologic Products Holdings Inc., BioIVT, PlasmaGen BioSciences Pvt. Ltd., Virchow Biotech Private Limited, LFB S.A., Intas Pharmaceuticals Ltd., Octapharma Plasma

Global Blood Plasma Derivatives Market Trends and Insights

Major companies operating in the blood plasma derivatives market are focused on supply chain innovation such as intravenous immunoglobulin, which allows for immune system support by providing functional antibodies to patients with immunodeficiency. Intravenous immunoglobulin (IVIg) refers to a medicine made from purified antibodies collected from the plasma of thousands of healthy donors for modulating the immune system. For instance, in August 2025, Octapharma, a Switzerland-based human protein products company, specializes in plasma-derived and recombinant therapies. Under the UK Plasma for Medicines Programme, launched Gamten 10% IVIg, an intravenous immunoglobulin (IVIg) product derived from UK-donated human plasma, designed to provide immunoglobulin replacement therapy for patients with primary or secondary immunodeficiency. Additionally, it also offers specialty therapies, including coagulation factors and critical care conditions.

What Are Latest Mergers And Acquisitions In The Blood Plasma Derivatives Market?

In October 2025, Accord Plasma B.V., a Netherlands based pharmaceutical company, acquired Prothya Biosolutions Belgium BV for an undisclosed amount. Through this acquisition of Prothya Biosolutions, Accord is allowed to gain full ownership of Prothya’s plasma fractionation facilities and plasma collection network, expand its global plasma-derived medicine capabilities, and strengthen its presence in Europe. Prothya Biosolutions is a Belgium-based biopharmaceutical company that produces several human blood plasma-derived medicinal products for use in immunology and critical care therapies.

Regional Outlook

North America was the largest region in the blood plasma derivatives market in 2025. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Blood Plasma Derivatives Market?

The blood plasma derivatives market consists of sales of fibrinogen, globulin, sodium, potassium, bicarbonate, and chloride. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Blood Plasma Derivatives Market Report 2026?

The blood plasma derivatives market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the blood plasma derivatives industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.